Optimization of gout therapy: advantages of using сolchicine
Summary. This article analyzes the current scientific and regulatory framework for optimizing gout therapy using colchicine at a dose of 0.6 mg. The history of colchicine use in Ukraine and the dosing challenges associated with traditional 0.5 mg and 1.0 mg doses — characterized by insufficient efficacy or a high risk of adverse effects, respectively — are discussed. Comparisons with international guidelines (ACR, EULAR, FDA) are presented, along with key clinical trial results, including the AGREE study and Borstad et al., which confirm the efficacy and safety of the 0.6 mg dose for managing acute attacks and preventing recurrent flares. Special considerations for patients with renal or hepatic impairment, elderly patients, and those with potential drug interactions are addressed. The study concludes that using colchicine 0.6 mg enables therapy standardization, reduces the risk of adverse effects, ensures rapid control of inflammation, prevents relapse, and improves patients’ quality of life. The practical significance of these findings lies in the implementation of an evidence-based, safe, and effective treatment regimen for gout in Ukrainian clinical practice.
Leave a comment